Alexion Pharmaceuticals, Inc. — Revenue by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7794ad1f-1339-41b8-909a-81e03e179414/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2020 | $6.1B | 2020-01-01 – 2020-12-31 | evidence 0000899866-21-000014 |
| FY 2019 | $5.0B | 2019-01-01 – 2019-12-31 | evidence 0000899866-20-000012 |
| FY 2018 | $4.1B | 2018-01-01 – 2018-12-31 | evidence 0000899866-19-000010 |
| FY 2017 | $3.6B | 2017-01-01 – 2017-12-31 | evidence 0000899866-19-000010 |
| FY 2016 | $3.1B | 2016-01-01 – 2016-12-31 | evidence 0000899866-19-000010 |
| FY 2015 | $2.6B | 2015-01-01 – 2015-12-31 | evidence 0000899866-17-000044 |
| FY 2014 | $2.2B | 2014-01-01 – 2014-12-31 | evidence 0000899866-17-000044 |
| FY 2013 | $1.6B | 2013-01-01 – 2013-12-31 | evidence 0000899866-16-000226 |
| FY 2012 | $1.1B | 2012-01-01 – 2012-12-31 | evidence 0000899866-13-000060 |
| FY 2011 | $783.4M | 2011-01-01 – 2011-12-31 | evidence 0001445305-12-000363 |
| FY 2010 | $541.0M | 2010-01-01 – 2010-12-31 | evidence 0001193125-11-039250 |
| FY 2009 | $386.8M | 2009-01-01 – 2009-12-31 | evidence 0001193125-11-039250 |
| FY 2008 | $259.0M | 2008-01-01 – 2008-12-31 | evidence 0001193125-11-039250 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Alexion Pharmaceuticals, Inc. — all facts · Net Income · Operating Income